Arrowhead Research reported $525.95M in Current Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agios Pharmaceuticals AGIO:US $ 1702.56M 652.55M
Alnylam Pharmaceuticals ALNY:US $ 2725.16M 255.08M
Anika Therapeutics ANIK:US $ 177.76M 4.29M
Arena Pharmaceuticals ARNA:US $ 990.44M 131.17M
Arrowhead Research ARWR:US $ 525.96M 60.8M
Bluebird Bio BLUE:US $ 903.53M 194.01M
Cerulean Pharma CERU:US $ 14.06M 4.46M
Dicerna Pharmaceuticals DRNA:US $ 616.49M 21.99M
Heron Therapeutics HRTX:US $ 366.83M 94.54M
Intercept Pharmaceuticals ICPT:US $ 493.1M 5.54M
Ligand Pharmaceuticals LGND:US $ 410.9M 26.53M
Mirati Therapeutics MRTX:US $ 1278.09M 25.42M
Moderna Inc MRNA:US 10.97B 734M
Nektar Therapeutics NKTR:US $ 1056.15M 42.9M
Novartis NOVN:VX 23.81B 1.61B
Opko Health OPK:US $ 547.03M 52.02M
Sarepta Therapeutics SRPT:US $ 2265.22M 6.13M
Spectrum Pharmaceuticals SPPI:US $ 165.71M 3.5M
Ultragenyx Pharmaceutical RARE:US $ 949.49M 121.44M
Vertex Pharmaceuticals VRTX:US $ 8457.51M 81.79M
Xencor XNCR:US $ 480.97M 110.2M
YTE INCY:US $ 2620.06M 170.09M